Lowering systolic BP to <120 mm Hg lowers risk by 26 percent
The management of patients hospitalized for novel coronavirus disease 2019 who develop an Acute COVID-19 Cardiovascular Syndrome should include surveillance and diagnostic strategies that balance potential patient risks and healthcare staff exposure with improvement in clinical outcomes.
Acute mental stress was found to elicit an abnormal P-wave axis in some individuals with stable coronary heart disease.
Pregnant women with heart disease were found to be at risk for serious cardiac events.
A single-lead handheld electrocardiogram device was found to achieve reproducible measurements of QTc intervals, through the capture of multiple vectors.
Dual therapy was found to be more effective in reducing the risk for bleeding in patients with atrial fibrillation who have undergone percutaneous coronary intervention, but may be associated with increased risk for ischemic events compared with triple therapy.
The occurrence of early-paroxysmal atrial fibrillation during acute myocardial infarction may not be associated with a higher risk for stroke.
Although not approved by the Food and Drug Administration (FDA) for COVID-19, hydroxychloroquine and azithromycin have been gaining momentum as potential treatments based on results of small studies.
Pectoral nerve blocks were found to diminish pain and opioid use following pacemaker or implantable cardioverter defibrillator placement in children.
Patients with transient ischemic attack with high brain natriuretic peptide values are more likely to have atrial fibrillation.